Related Experiment Video

Updated: May 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

New hormonal therapies for castration-resistant prostate cancer

Elahe A Mostaghel1, Stephen Plymate

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Endocrinology and Metabolism Clinics of North America
|September 6, 2011
PubMed

Insights

Castration-resistant prostate cancer (CRPC) progresses due to continued androgen receptor (AR) activation. Novel therapies targeting AR signaling are crucial for improving treatment efficacy and preventing disease advancement.

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Continued activation of the androgen receptor (AR) axis despite castration drives castration-resistant prostate cancer (CRPC) progression.
  • Tumor-specific alterations in AR expression/activity and steroidogenic pathways contribute to CRPC development.
  • Effective therapeutic strategies to inhibit tumoral androgen activity are needed.

Purpose of the Study:

  • To review AR and ligand-dependent mechanisms underlying CRPC progression.
  • To discuss novel hormonal therapies targeting the AR axis in clinical and preclinical development.

Main Methods:

  • Literature review of studies on androgen receptor signaling in prostate cancer.
  • Analysis of mechanisms driving castration resistance.
  • Survey of current and emerging therapeutic strategies targeting the AR axis.

Main Results:

  • Identified AR axis activation and ligand generation pathways as key drivers of CRPC.
  • Summarized the status of various novel hormonal therapies targeting the AR axis.
  • Highlighted the need for improved therapeutic strategies to overcome resistance mechanisms.

Conclusions:

  • Understanding AR and ligand-dependent mechanisms is critical for developing effective CRPC treatments.
  • Novel hormonal therapies targeting the AR axis show promise but require further investigation.
  • Continued research into AR signaling and resistance pathways is essential for improving patient outcomes.

More Related Videos

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...